High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 69-74

  Bengala, C ^a   Pazzagli, I ^a   Innocenti, F ^a   Donati, S ^a   Favre, C ^a   Menconi, M C ^a   Greco, F ^a   Danesi, R ^a   Orlandini, C ^a   Guarneri, V ^a   Tacca, M D ^a   Conte, P F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

High dose chemotherapy; Metastatic breast cancer; Paclitaxel

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; AMIKACIN; ANTHRACYCLINE; CD34 ANTIGEN; CEFTAZIDIME; CIPROFLOXACIN; CYTOTOXIC AGENT; DEXAMETHASONE; EPIRUBICIN; FLUCONAZOLE; GEMCITABINE; MELPHALAN; ONDANSETRON; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOTRANSPLANTATION; BREAST METASTASIS; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CELL CLONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; DRUG RESISTANCE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFUSION; MONITORING; MUCOSA INFLAMMATION; NEUTROPHIL; PARAMETER; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0035114663     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008302402687     Document Type: Article

References (28)

1. Phase III randomized trial of high-dose chemotherapy (HDC) and stem-cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (PBT-1)
2. High-dose chemotherapy (HD-CT) with hematopoietic stem-cell transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French Protocol PEGASE 04
3. Tumor stem cell heterogeneity: Implication with respect to classification of cancer by chemotherapeutic effect
4. Alkylating agents. In vitro studies of cross-resistance patterns in human tumor cell lines
5. Dose-intensive therapy in breast cancer
6. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: A feasibility study
7. Tandem high-dose chemotherapy in women with stage IV breast cancer
8. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over three hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
9. Gemcitabine, epirubicin, and Taxol (GET) followed by high-dose chemotherapy (HDCT): High activity with good tolerability in metastatic breast cancer patients
10. Mobilization, collection and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel and granulocyte colony-stimulating factor administered to patients with metastatic breast cancer
11. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: Pharmacokinetics and toxicity
12. Dosing of thiotepa for myeloablative therapy
13. Cardiotoxicity of epirubicin-Taxol containing regimens: Role of cardiac risk factor
14. -triethylenethiophosphoramide in human plasma
15. High pressure liquid chromatographic method for the determination of melphalan in plasma
16. Cardiac complications after bone marrow transplantation
17. Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant
18. Cyclophosphamide cardiotoxicity: Analysis of dosing as risk factor
19. Cardiac and respiratory function after bone marrow transplantation in children with leukemia
20. High-dose intravenous melphalan: A review
21. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation
22. Phase I/pharmacokinetic re-evaluation of thiotepa
23. Modulation of thiotepa anti-tumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism
24. The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkilating cytostatic drug thiotepa
25. Factors predicting long term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support
26. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer
27. Factors correlated with prograssion-free survival survival after high-dose chemotherapy and hemopoietic stem-cell transplantation for metastatic breast cancer
28. High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients